Northwest Biotherapeutics, Inc. (NWBO)

forse ma forse hanno fatto uscire le mani deboli
x toccare il dollaro????

vedremo$$$$$$$$$$$$$$$$
 
è qua che si gioca il tutto
non guardare il prezzo adesso(puo essere un affare come no)

hanno in mano un prodotto!
NorthWest Bio DCVax-L Brain Cancer Treatment is Helping Patients live 6 and pass 10 years when life expediency is just 8.9 months to 14.9 months without it. Northwest Bio has a very good Cancer Treatment. Their Website shows the progress of patient from Phase 1 to phase 111 who are using DCVax-L living loner productive lives. Less Go NWBO !!

NEWS OUT at ANYTIME Today or before Conference Tomorrow Morning in London.


http://www.nwbio.com/clinical-trials/
 
NASDAQ:NWBO

Dear Axelvento,

Attached you will find our Release on Dr. Marnix Bosch’s presentation today at the 5th Annual SMi Cancer Vaccines Conference in London on updated data from our DCVax-Direct Phase I Trial.

This Release summarizes some of the highlights of the data, including the longer than expected survival times, as well as analyses of the underlying mechanisms of action and the cellular and immune profiles.

We certainly remain encouraged by these results in a population of patients with multiple inoperable tumors for which there are no effective treatments today.

As indicated in the Release, the presentation slides by our Chief Technical Officer can be found on our website as well.

All the best,





Leslie J. Goldman
Senior Vice President for Business Development



For immediate release


NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial
At 5th Annual SMi Cancer Vaccines Conference in London
Dr. Marnix Bosch, Chief Technical Officer, Presented

BETHESDA, MD, September 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines Conference in London, England.

DC Vax-Direct is designed to treat inoperable solid tumors. The Phase I Trial treated patients with multiple inoperable metastatic tumors who had failed existing treatment regimens. These patients had failed as many as five or six different prior types of treatments, and had generally quite poor life expectancies when they entered the DCVax-Direct Trial. DCVax-Direct was directly injected, with image guidance, into just one of the patients’ tumors and most patients received just three treatments. The Trial included 40 patients, with 39 evaluable, and covered more than a dozen diverse types of solid tumor cancers.

Some highlights of Dr. Bosch’s update presentation today included:

The top 20% of these patients have so far exceeded 2 years of survival and are still alive. The longest survivor to date has reached nearly 3 years. See Attachment A for details.
The top 30% of these patients (including pancreatic, melanoma, lung, ovarian, sarcoma and other cancers) as a combined group have an average survival to date of 26.7 months, compared with an average of expected survival times of 12.3 months. Individually, these patients have also substantially exceeded their respective expected survival times. See Attachment B for details.
The continuing positive survival results correlate with underlying mechanisms of action and cellular and immune profiles, including phenotype analyses, relative production of a wide range of diverse cytokines by the dendritic cells. Additional positive observations include T-cell infiltration, and PD-L1 expression.
64% of the patients evaluable for PD-L1 checkpoint expression (14 of 22) showed either de novo or significantly increased expression of PD-L1 following DCVax-Direct treatment, indicating potential for combination of DCVax-Direct and checkpoint inhibitors.
The diverse cancers covered in this trial are responsible for approximately 800,000 new cases annually in the US and also at least 800,000 new cases in Europe. When these cancers reach the inoperable metastatic stage, there are no effective treatments available today.

There was no webcast of the presentation, but Dr. Bosch’s slides will be available on the NW Bio website starting today.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients. GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors cancers. It has completed enrollment in the Phase I portion of the trial. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.
 
mi diverte assai leggere tutte queste cose positive e negative
Northwest Biotherapeutics, Inc (NASDAQ:NWBO): Heading For A Reversal? | Insider Financial


ALLA FINE QUELLA CHE DETTA LEGGE
è LA GRANDE MA.FI.A
F.D.A

NON NOI

lo sanno pure i muri che questa e' una scommessa anche molto rischiosa puo' tornare a 3$ come finire nel cesso...oggi sono rientrato a 0,44 non molto convinto perche' non c'e piu' speculazione...investito solo il gain dell'ultimo forte rimbalzo...quindi sono molto tranquillo..
 
uscito al 100%..provo a rientrare a 0,30...societa' alla canna del gas....


BETHESDA, Md., Oct. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a definitive agreement with an institutional investor for a registered direct offering with gross proceeds of approximately $5million. The proceeds will be used in connection with upcoming Phase II clinical trials.
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)

Pursuant to the agreement, the Company has agreed to sell to the investor up to 14 million shares of the Company's Common Stock at a purchase price of $0.38 per share.

The sale of the shares is expected to close on or about October 26, 2016, subject to satisfaction of customary closing conditions. Roth Capital Partners acted as the exclusive placement agent for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-213777), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 18, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at SEC.gov | Home

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients. GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors cancers. It has completed the Phase I portion of the trial. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as changes in market condition or the failure of the Company to satisfy the closing conditions set forth in the purchase agreement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
 
uscito al 100%..provo a rientrare a 0,30...societa' alla canna del gas....


BETHESDA, Md., Oct. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a definitive agreement with an institutional investor for a registered direct offering with gross proceeds of approximately $5million. The proceeds will be used in connection with upcoming Phase II clinical trials.
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)

Pursuant to the agreement, the Company has agreed to sell to the investor up to 14 million shares of the Company's Common Stock at a purchase price of $0.38 per share.

The sale of the shares is expected to close on or about October 26, 2016, subject to satisfaction of customary closing conditions. Roth Capital Partners acted as the exclusive placement agent for the offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-213777), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 18, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at SEC.gov | Home

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients. GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors cancers. It has completed the Phase I portion of the trial. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as changes in market condition or the failure of the Company to satisfy the closing conditions set forth in the purchase agreement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


direzione quasi sicura a 0,38.
però hanno ottenuto dei soldi...$5million.
 
direzione quasi sicura a 0,38.
però hanno ottenuto dei soldi...$5million.
ma questi bruciano cassa clamorosamente entro solo a 0,30 per un pompaggio per la prossima diluzione.....come a capitato da 0,32 tanto a breve arriva il rs....penso 20 x1....in questo settore tutto e' possibile ma e' piu' facile che finisca in otc che ritorni a 2$opinione personale che non vale un gazzo..
 
NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

PR Newswire PR NewswireDecember 8, 2016
BETHESDA, Md., Dec. 7, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company's plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw the Company's common stock from listing on Nasdaq. Upon withdrawal from Nasdaq, the Company plans to begin trading on the over-the-counter (OTC) market.

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
More
Pursuant to Nasdaq Listing Rule 5840(j), the Company is required to give Nasdaq ten days' notice of the voluntary withdrawal, and this period cannot be shortened. As a result, trading on Nasdaq is expected to be suspended on or about December 19, 2016, and trading in the Company's stock on the OTC is expected to begin the same day, as the Company anticipates a seamless transition.

The Company will file a Form 25 with the Securities and Exchange Commission on December 19. The delisting is expected to become effective 10 calendar days later. During this 10-day period, the Company's stock is anticipated to be trading on the OTC market.

The Company has had discussions with the Staff of OTC Markets Group Inc. and believes that it currently satisfies all requirements for trading on The OTCQB Venture Market (the "OTCQB"). Accordingly, the Company plans to promptly file an application to be traded on that market.

The Company desires to proceed with multiple Phase 2 trials in addition to completing its current Phase 3 trial. The Company believes that it will have enhanced ability to raise the funding required for these programs on the OTC as compared with the Nasdaq as the Company will not be subject to the type of the restrictions on its ability to accept financing on the OTC that it has been subject to on Nasdaq. If the Company were to remain listed on Nasdaq, the Company's understanding is that the aggregation of the financings completed by the Company since May of this year would likely be deemed to preclude any substantial further fundraising until at least sometime in Q1 of 2017.

As previously reported, on November 7, 2016 the Company received a letter from the Nasdaq Staff indicating that the Staff had determined to aggregate a series of financing transactions that were completed between May 15, 2016 and October 13, 2016, although the transactions were in many cases small and diverse, and involved a number of unrelated parties. Based upon the aggregation, the Nasdaq Staff determined that the transactions did not comply with Nasdaq's Listing Rule 5635(d) since, in the aggregate, they exceeded 20% of the number of shares outstanding prior to May 15, 2016. The Company engaged in remediation discussions with the Nasdaq Staff. However, the Nasdaq Staff ultimately determined not to accept the Company's proposed plan of remediation. As noted above, given that the Nasdaq Staff determined to aggregate these transactions and that the last transaction did not occur until October 13, 2016, the Company's understanding is that it would likely be foreclosed from completing further significant financings until at least sometime in Q1 2017.

Read More



HA FATTO ANDATA E RITORNO IN OTC....DA SEGUIRE
 
NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

PR Newswire PR NewswireDecember 8, 2016
BETHESDA, Md., Dec. 7, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company's plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw the Company's common stock from listing on Nasdaq. Upon withdrawal from Nasdaq, the Company plans to begin trading on the over-the-counter (OTC) market.

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
More
Pursuant to Nasdaq Listing Rule 5840(j), the Company is required to give Nasdaq ten days' notice of the voluntary withdrawal, and this period cannot be shortened. As a result, trading on Nasdaq is expected to be suspended on or about December 19, 2016, and trading in the Company's stock on the OTC is expected to begin the same day, as the Company anticipates a seamless transition.

The Company will file a Form 25 with the Securities and Exchange Commission on December 19. The delisting is expected to become effective 10 calendar days later. During this 10-day period, the Company's stock is anticipated to be trading on the OTC market.

The Company has had discussions with the Staff of OTC Markets Group Inc. and believes that it currently satisfies all requirements for trading on The OTCQB Venture Market (the "OTCQB"). Accordingly, the Company plans to promptly file an application to be traded on that market.

The Company desires to proceed with multiple Phase 2 trials in addition to completing its current Phase 3 trial. The Company believes that it will have enhanced ability to raise the funding required for these programs on the OTC as compared with the Nasdaq as the Company will not be subject to the type of the restrictions on its ability to accept financing on the OTC that it has been subject to on Nasdaq. If the Company were to remain listed on Nasdaq, the Company's understanding is that the aggregation of the financings completed by the Company since May of this year would likely be deemed to preclude any substantial further fundraising until at least sometime in Q1 of 2017.

As previously reported, on November 7, 2016 the Company received a letter from the Nasdaq Staff indicating that the Staff had determined to aggregate a series of financing transactions that were completed between May 15, 2016 and October 13, 2016, although the transactions were in many cases small and diverse, and involved a number of unrelated parties. Based upon the aggregation, the Nasdaq Staff determined that the transactions did not comply with Nasdaq's Listing Rule 5635(d) since, in the aggregate, they exceeded 20% of the number of shares outstanding prior to May 15, 2016. The Company engaged in remediation discussions with the Nasdaq Staff. However, the Nasdaq Staff ultimately determined not to accept the Company's proposed plan of remediation. As noted above, given that the Nasdaq Staff determined to aggregate these transactions and that the last transaction did not occur until October 13, 2016, the Company's understanding is that it would likely be foreclosed from completing further significant financings until at least sometime in Q1 2017.

Read More



HA FATTO ANDATA E RITORNO IN OTC....DA SEGUIRE


scattate le ricoperture short..era prevedibile...forse in otc non e' possibile ricoprirsi???
 
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

As discussed in Item 3.01 herein, on December 7, 2016, Northwest Biotherapeutics, Inc. (the “Company”) notified the Nasdaq Stock Market (“Nasdaq”) of its intention to voluntarily withdraw the Company’s common stock from listing on the Nasdaq Capital Market.

Ceasing to be listed or quoted on Nasdaq will constitute a “Fundamental Change” pursuant to the indenture (“Indenture”) relating to the Company’s Convertible Senior Notes (the “Notes”) that were issued in August, 2014 and are otherwise due in August, 2017. In accordance with the terms of the Indenture, the Company will be obligated to make an offer to repurchase the Notes for cash in accordance with the terms of the Indenture within a period of 20 business days following this change. The aggregate principal amount of the Notes outstanding is $11.0 million. The Company has begun to evaluate its options to finance the repurchase of the Notes, although there can be no assurance that such options will be available or will be on acceptable terms. If the Company fails to satisfy its obligations, such failure would result in an event of default under the Notes.

The voluntary withdrawal of the Company’s common stock from listing on Nasdaq also will constitute a “Make-Whole Fundamental Change” under the Indenture. As a result, beginning on December 12, 2016, holders of the Notes will have the right to convert their Notes in accordance with the terms of the Indenture. This conversion right will continue until the later of: (i) 5:00 p.m., New York City time, on the business day that is on the 30th scheduled trading day immediately following the actual effective date of the delisting and (ii) 5:00 p.m., New York City time, on the business day immediately preceding the fundamental change repurchase date relating to the delisting.

Because the current trading price of the Company’s common stock is below $6.004 per share, the Company does not presently anticipate that any “Make-Whole Conversion Rate Adjustment” (as defined in the Indenture) will be required in connection with the Make-Whole Fundamental Change. Pursuant the Indenture, the Company has the right to settle any conversions, at its election, in cash, shares of common stock, or a combination thereof. To the extent any Notes are converted in connection with the Make-Whole Fundamental Change, the Company intends to settle any such conversions solely in shares of common stock (plus cash in lieu of fractional shares). The closing price of the Company’s common stock on December 8, 2016 was $0.58 per share. The conversion price in respect of the Notes is $6.60 per share.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On December 7, 2016, the Company notified the Nasdaq of its intention to voluntarily withdraw the Company’s common stock from listing on the Nasdaq Capital Market. The Company intends to file Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act, with the Securities and Exchange Commission (the “SEC”) on December 19, 2016, and expects trading in its common stock on Nasdaq to be suspended at that time. The Company further expects that the delisting will become effective ten days from the filing of the Form 25 with the SEC, or on or about December 29, 2016. The Company is also voluntarily withdrawing from listing on Nasdaq its series of warrants to purchase common stock that are traded on Nasdaq. The Company anticipates that its common stock will be quoted on the OTC market at the time trading in its common stock on Nasdaq is suspended.

A copy of the press release, dated December 7, 2016, announcing the Company’s intention to voluntarily withdraw the Company's common stock from listing on Nasdaq is included as Exhibit 99.1 and is incorporated herein by reference.
 
Otc,,,,,,otc.......ora possono diluire in santa pace......
 
Otc,,,,,,otc.......ora possono diluire in santa pace......

NW BIO ANNUNCIA UN'OFFERTA DIRETTA REGISTRATO DI $ 10,0 milioni con gli investitori istituzionali

il ritorno in otc potrebbe essere interessante sono fuori ma la seguo...vediamo dove potrebbe toccare il fondo...axe come la vedi la situazione??
 
Linda Liau responds to investor concerns regarding 12/15/16 Seattle presentation. In an email exchange between an investor and Linda Liau, Dr. Liau offers clarification regarding her comments from the presentation.

Quote:

Question
Dear Dr. Liau: In your video last week (and also last year), your comments seemed quite positive about the patients living longer, but last week you also seemed to say that DCVax would not be able to get FDA approval. Is that what you really meant? How could that be the case if patients are living longer? Would love to have clarification on this issue

Thank you in advance for your time .
Xxxxxx xxxxxxxx


Dr. Liau's answer

Hi Xxxxxx,

Yes, the patients do seem to be living longer with DCVax; and no, I did not mean to say that DCVax would not get FDA approval. I was making the point that, whether or not the study fits a particular category endpoint, there should be a way to get approval if the data shows that the entire group of DCVax patients (in both arms) does better than concurrent/historical controls who have not gotten DCVax.

Hope this clarifies the issue.

Thanks,
LL


Linda M. Liau, M.D., Ph.D., M.B.A.
Professor & Vice Chair of Neurosurgery

Director, UCLA Brain Tumor Program

UCLA Department of Neurosurgery
Sent from my iPhone



This investor doesn’t post on the boards, and decided to forward me the above email exchange with Dr. Liau regarding a question the investor had asked her in an email. The investor was concerned as a result of her Seattle presentation that Linda Liau was of the impression that DCVax-L would not be eligible for FDA approval despite the fact that these patients were all living longer.

Dr. Liau’s response to the query is important, and I don’t believe this person had actually anticipated receiving a response from her, let alone a response as quickly as it was given.

So this person forwarded the entire query and response to me because this investor felt what Dr. Liau wrote was very relevant to all other investors as well. And since this investor knows I do post on the boards, this seemed the best way to share it.

And I know a few of you will wonder why this person couldn’t just post it themselves. The answer is that this investor doesn’t post, has never posted, and most of you would not be familiar with this person anyway. The investor decided that having me post this exchange with Dr. Liau would be the best way to get out LL’s self-described clarification on this “issue” to all of us.
 
Buongiorno,
Chiedo a chi conosce un po' il titolo se ci sono novità. Mi sembra di aver capito che il rilascio dei dati sia vicino.

Grazie
 
entrato con 5000 pezzi a 0,23 tanto per non dimenticare oggi altro stampaggio di carta igienica..[url=http://finance.yahoo.com/news/nw

Ciao,
hai idea di quanto cash hanno in cassa e fino a dove vanno in termini di tempo, con quello recuperato in questi giorni? Secondo te arriviamo alla pubblicazione dei dati di fase III?
 
Indietro